Monitor for next DSMB update or efficacy data readout from the Phase 3 Bria-ABC study. No near-term catalyst date provided; stock likely to remain range-bound until meaningful efficacy or safety signals emerge.
Price Chart
Executive Summary
BriaCell announced its seventh consecutive positive DSMB recommendation for the pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer. The DSMB raised no safety concerns and recommended continuation without modifications. This is a routine procedural update for a clinical-stage biotech with an $8M market cap and no revenue, providing incremental positive safety data but no efficacy readout or catalyst date.
Key Facts
- Seventh consecutive positive DSMB recommendation for Phase 3 Bria-ABC study of Bria-IMT plus CPI in metastatic breast cancer
- DSMB raised no safety or other clinical concerns and recommended study continue without modifications
- Study conducted under FDA Fast Track designation
- DSMB meetings occur quarterly per study protocol
- No efficacy data, no catalyst date, no financial figures disclosed
Financial Impact
No financial impact disclosed; clinical-stage company with $8M market cap and no revenue
Risk Factors
- Phase 3 trial may fail to meet efficacy endpoints despite favorable safety profile
- Clinical-stage biotech with no approved products or revenue
- Low market cap ($8M) increases volatility risk on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers